Cargando…
Visual Outcome of Anti-vascular Endothelial Growth Factor Injections at the University College Hospital, Ibadan
AIM: The aim of the study was to evaluate the 1-year outcome of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy in an eye unit in sub-Saharan Africa. METHODOLOGY: This retrospective study included 182 eyes of 172 patients managed in the vitreoretinal unit between 2016 and 20...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693741/ https://www.ncbi.nlm.nih.gov/pubmed/34893565 http://dx.doi.org/10.4103/aam.aam_61_20 |
_version_ | 1784619204733829120 |
---|---|
author | Oluleye, Tunji Sunday Babalola, Yewande Olubunmi Majekodunmi, Oluwole Ijaduola, Modupe Adewole, Adeyemi Timothy |
author_facet | Oluleye, Tunji Sunday Babalola, Yewande Olubunmi Majekodunmi, Oluwole Ijaduola, Modupe Adewole, Adeyemi Timothy |
author_sort | Oluleye, Tunji Sunday |
collection | PubMed |
description | AIM: The aim of the study was to evaluate the 1-year outcome of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy in an eye unit in sub-Saharan Africa. METHODOLOGY: This retrospective study included 182 eyes of 172 patients managed in the vitreoretinal unit between 2016 and 2019 who were treated with intravitreal anti-VEGF bevacizumab (1.25 mg/0.05 ml) with at least 1 year of follow-up. The outcome measures were change in best-corrected visual acuity (BCVA) over 1 year of follow-up, the number of injections taken, and complications. RESULTS: The mean age was 61.1 ± 16.3 years (male-to-female ratio of 1:1.1) and about 62.1% above >60 years. A total of 330 injections were given during the period audited. The mean number of injections was 1.8 ± 0.93. Ninety-four (51.7%) eyes had only one injection, while 33 (18.1%), 50 (27.5%), and 5 (2.7%) had 2, 3, and 4 injections, respectively. About 78.5% had moderate-to-severe visual impairment at baseline and 44.5%, 16.4%, 12.6%, and 7.1% at 1, 3, 6, and 12 months post injections, respectively. The mean BCVA improved for all eyes from 1.67 ± 0.91 logarithm of minimum angle of resolution (logMAR) at baseline to 1.50 ± 1.27 logMAR at 1 year. The logMAR letters gained was 23 at 1 month and 8.25 at 1 year; the eyes that had three injections gained 10 letters, while those that had one injection gained three letters. Eyes with age-related macular degeneration and idiopathic polypoidal choroidopathy gained 7.5 and 9 letters, respectively, at 1 year after at least three injections. There was a statistically significant association between an increasing number of injections and improved visual outcome (P = 0.043). One patient each developed endophthalmitis (0.6%) and inferior retinal detachment (0.6%) post injection. CONCLUSION: Visual acuity gain was recorded in patients who had intravitreal anti-VEGF injections in 1 year. It is recommended that patients should have more than one injection. |
format | Online Article Text |
id | pubmed-8693741 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-86937412022-01-10 Visual Outcome of Anti-vascular Endothelial Growth Factor Injections at the University College Hospital, Ibadan Oluleye, Tunji Sunday Babalola, Yewande Olubunmi Majekodunmi, Oluwole Ijaduola, Modupe Adewole, Adeyemi Timothy Ann Afr Med Original Article AIM: The aim of the study was to evaluate the 1-year outcome of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy in an eye unit in sub-Saharan Africa. METHODOLOGY: This retrospective study included 182 eyes of 172 patients managed in the vitreoretinal unit between 2016 and 2019 who were treated with intravitreal anti-VEGF bevacizumab (1.25 mg/0.05 ml) with at least 1 year of follow-up. The outcome measures were change in best-corrected visual acuity (BCVA) over 1 year of follow-up, the number of injections taken, and complications. RESULTS: The mean age was 61.1 ± 16.3 years (male-to-female ratio of 1:1.1) and about 62.1% above >60 years. A total of 330 injections were given during the period audited. The mean number of injections was 1.8 ± 0.93. Ninety-four (51.7%) eyes had only one injection, while 33 (18.1%), 50 (27.5%), and 5 (2.7%) had 2, 3, and 4 injections, respectively. About 78.5% had moderate-to-severe visual impairment at baseline and 44.5%, 16.4%, 12.6%, and 7.1% at 1, 3, 6, and 12 months post injections, respectively. The mean BCVA improved for all eyes from 1.67 ± 0.91 logarithm of minimum angle of resolution (logMAR) at baseline to 1.50 ± 1.27 logMAR at 1 year. The logMAR letters gained was 23 at 1 month and 8.25 at 1 year; the eyes that had three injections gained 10 letters, while those that had one injection gained three letters. Eyes with age-related macular degeneration and idiopathic polypoidal choroidopathy gained 7.5 and 9 letters, respectively, at 1 year after at least three injections. There was a statistically significant association between an increasing number of injections and improved visual outcome (P = 0.043). One patient each developed endophthalmitis (0.6%) and inferior retinal detachment (0.6%) post injection. CONCLUSION: Visual acuity gain was recorded in patients who had intravitreal anti-VEGF injections in 1 year. It is recommended that patients should have more than one injection. Wolters Kluwer - Medknow 2021 2021-12-03 /pmc/articles/PMC8693741/ /pubmed/34893565 http://dx.doi.org/10.4103/aam.aam_61_20 Text en Copyright: © 2021 Annals of African Medicine https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Oluleye, Tunji Sunday Babalola, Yewande Olubunmi Majekodunmi, Oluwole Ijaduola, Modupe Adewole, Adeyemi Timothy Visual Outcome of Anti-vascular Endothelial Growth Factor Injections at the University College Hospital, Ibadan |
title | Visual Outcome of Anti-vascular Endothelial Growth Factor Injections at the University College Hospital, Ibadan |
title_full | Visual Outcome of Anti-vascular Endothelial Growth Factor Injections at the University College Hospital, Ibadan |
title_fullStr | Visual Outcome of Anti-vascular Endothelial Growth Factor Injections at the University College Hospital, Ibadan |
title_full_unstemmed | Visual Outcome of Anti-vascular Endothelial Growth Factor Injections at the University College Hospital, Ibadan |
title_short | Visual Outcome of Anti-vascular Endothelial Growth Factor Injections at the University College Hospital, Ibadan |
title_sort | visual outcome of anti-vascular endothelial growth factor injections at the university college hospital, ibadan |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693741/ https://www.ncbi.nlm.nih.gov/pubmed/34893565 http://dx.doi.org/10.4103/aam.aam_61_20 |
work_keys_str_mv | AT oluleyetunjisunday visualoutcomeofantivascularendothelialgrowthfactorinjectionsattheuniversitycollegehospitalibadan AT babalolayewandeolubunmi visualoutcomeofantivascularendothelialgrowthfactorinjectionsattheuniversitycollegehospitalibadan AT majekodunmioluwole visualoutcomeofantivascularendothelialgrowthfactorinjectionsattheuniversitycollegehospitalibadan AT ijaduolamodupe visualoutcomeofantivascularendothelialgrowthfactorinjectionsattheuniversitycollegehospitalibadan AT adewoleadeyemitimothy visualoutcomeofantivascularendothelialgrowthfactorinjectionsattheuniversitycollegehospitalibadan |